FDA 2026 Peptide Reclassification: What the Category 1 Compounding Ruling Means for Patients
The FDA's 2026 action returns roughly 14 peptides to Category 1 compounding eligibility. A physician explains what changed, which peptides are affected, and what this means for your access.